title: [The value of intraluminal brachytherapy in the treatment for esophageal cancer].
abstract: To control dysphagia 202 patients with a verified esophageal cancer of stage cT1-4N0-2M0-1 underwent intraluminal brachytherapy with neoadjuvant chemoradiotherapy in the process of combined radiation/chemoradiation therapy and palliative treatment. Duration of event-free period in the group of patients, operated after neoadjuvant chemoradiotherapy was 10,1 ± 2,7 months, after intraluminal brachytherapy at combined radiation/chemoradiation therapy was 6,2 ± 2,6 months and at palliative brachytherapy--4,5 ± 2,0 months. Frequency of complete clinical regressions was 16,7% after neoadjuvant chemoradiotherapy, 19,3% after brachytherapy in the frames of radiation/chemoradiation therapy for esophageal cancer, 15,7% as a result of palliative intraluminal brachytherapy. Complete morphological tumor regression after neoadjuvant chemoradiotherapy using intraluminal brachytherapy was registered in 23,1% patients.
authors.forename: S V
authors.initials: SV
authors.lastname: Kanaev
authors.forename: E I
authors.initials: EI
authors.lastname: Tyuryaeva
authors.forename: E V
authors.initials: EV
authors.lastname: Levchenko
authors.forename: S Yu
authors.initials: SY
authors.lastname: Dvoretsky
authors.forename: A M
authors.initials: AM
authors.lastname: Shcherbakov
authors.forename: A A
authors.initials: AA
authors.lastname: Avanesyan
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy; D059186:Chemoradiotherapy, Adjuvant; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods; D016019:Survival Analysis; D016896:Treatment Outcome